Apogee Therapeutics (APGE) Other Accumulated Expenses (2022 - 2024)

Apogee Therapeutics (APGE) has 3 years of Other Accumulated Expenses data on file, last reported at $1.7 million in Q3 2024.

• Other Accumulated Expenses for Q3 2024 came in at $1.7 million, up 144.65% year-over-year; the trailing twelve-month figure through Sep 2024 was $1.7 million (up 144.65% YoY), and the FY2023 annual result was $1.2 million, up 521.5% from the prior year.
• Other Accumulated Expenses rose to $1.7 million in Q3 2024 per APGE's latest filing, from $1.0 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $2.1 million in Q1 2024 and troughed at $200000.0 in Q4 2022.
• A 3-year average of $1.3 million and a median of $1.2 million in 2023 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses soared 521.5% in 2023, then sank 44.94% in 2024.
• A 3-year view of Other Accumulated Expenses shows it stood at $200000.0 in 2022, then soared by 521.5% to $1.2 million in 2023, then jumped by 36.2% to $1.7 million in 2024.
• Business Quant data shows APGE's Other Accumulated Expenses at $1.7 million in Q3 2024, $1.0 million in Q2 2024, and $2.1 million in Q1 2024.